Short answer
TransMedics Group, Inc. (TMDX) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $174M (up 21.2% year over year) with net income of $7M.
Q1 2026 key financials · XBRL
- Revenue
- $174M
- +21.2% YoY
- Net income
- $7M
- −71.5% YoY
- Operating margin
- 7.6%
- Gross margin
- 58.2%
- EPS (diluted)
- $0.20
- −71.4% YoY
Source: XBRL data from the TransMedics Group, Inc. (TMDX) Q1 2026 10-Q on SEC EDGAR. USD.
TransMedics Group, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $173.9M, up $30.4M YoY from $143.5M, driven by Liver revenue and NOP usage
- Overall gross margin 58% vs 61% YoY; product margin 77% vs 82%, service margin 27% vs 29%
- Best segment Liver revenue $149.0M vs $108.9M; worst Lung revenue $2.8M vs $4.0M
- Cash $461.7M; operating cash flow $24.5M vs $(2.9)M YoY; investing outflow $36.7M
- Outlook: long-term revenue growth expected; higher operating expenditures, tax rate, tariff and freight-cost headwinds
Risk Factors
- No Risk Factors section provided in the submitted excerpt
- Newly disclosed director 10b5-1 plan authorizes sale of 15,934 common shares
- Trading plan adopted March 4, 2026, with trading scheduled from June 24, 2026 to May 25, 2027
- January 30, 2026 executive retention agreements introduced for Giovanni Cecere and Matthew Forsyth
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TransMedics Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.